The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has infected over 12 million individuals and caused more than 55,200 death worldwide. Currently, there is no specific drug to treating this disease. Here we summarized the mechanisms of antiviral therapies and the clinic findings from different countries. Antiviral chemotherapies have been conducted by in multiple cohorts in different counties. Although FDA has fast approved remdesivir for treating COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality. The chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its in vitro antiviral effects, it is imperative high-quality data from worldwide clinical trials are necessitated for an approved therapy. In terms of hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients, large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the virus. Convalescent plasma (CP) therapy suggested its safety use in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or ex vivo human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating highly effective therapies.

由新型冠状病毒 SARS-CoV-2 感染引起的大流行性 COVID-19 已在全球范围内感染了超过 1200 万人，并导致超过 55,200 人死亡。目前，没有特效药物可以治疗这种疾病。在这里，我们总结了抗病毒治疗的机制以及不同国家的临床发现。抗病毒化疗已在不同县的多个队列中进行。尽管 FDA 已快速批准瑞德西韦用于治疗 COVID-19，但它只能加快 COVID-19 的康复速度，并略微降低死亡率。由于其体外抗病毒作用，氯喹被认为是对抗 SARS-CoV-2 感染的潜在药物，因此批准的疗法必须获得全球临床试验的高质量数据。就羟氯喹（HCQ）治疗而言，尽管世卫组织因其对新冠患者的强烈副作用而停止了所有临床试验，但具有长期结果随访的大规模临床试验可能需要HCQ和阿奇霉素联合用于对抗新冠肺炎。病毒。恢复期血浆（CP）疗法表明其在 SARS-CoV-2 感染中的安全使用；但 CP 免疫疗法和 NK 细胞疗法都必须根据严格的道德和受控条件来生产和使用，以保证这些人类来源产品的可能作用。应该进行进一步的研究来明确 SARS-CoV-2 发病的确切机制，合适的动物模型或离体人体肺组织有助于研究新型病毒的复制、传播和传播，从而促进高效的治疗。